ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 12
- Registration Number
- NCT01563536
- Locations
- 🇺🇸
Site Reference ID/Investigator# 67385, Poughkeepsie, New York, United States
🇺🇸Site Reference ID/Investigator# 67382, Annapolis, Maryland, United States
🇺🇸Site Reference ID/Investigator# 67383, Orlando, Florida, United States
Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Adalimumab
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 64
- Registration Number
- NCT01561313
- Locations
- 🇧🇪
Site Reference ID/Investigator# 63360, Ghent, Belgium
🇧🇪Site Reference ID/Investigator# 63357, Genk, Belgium
🇨🇿Site Reference ID/Investigator# 63361, Uherske Hradiste, Czech Republic
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Non-Small -Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 160
- Registration Number
- NCT01560104
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 483
- Registration Number
- NCT01559038
- Locations
- 🇨🇦
Pont, Cranbrook, BC, CA /ID# 69120, Cranbrook, British Columbia, Canada
🇨🇦Hudson, Kamloops, Canada /ID# 69104, Kamloops, British Columbia, Canada
🇨🇦Dr. Maqbool R. Sheriff Inc. /ID# 69125, Nanaimo, British Columbia, Canada
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 17
- Registration Number
- NCT01557777
- Locations
- 🇮🇱
Site Reference ID/Investigator# 77637, Rechovot, Israel
🇺🇸Site Reference ID/Investigator# 74036, La Jolla, California, United States
🇺🇸Site Reference ID/Investigator# 74033, Bethesda, Maryland, United States
A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: Adalimumab
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 463
- Registration Number
- NCT01550965
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 434
- Registration Number
- NCT01549834
- Locations
- 🇺🇸
Site Reference ID/Investigator# 66531, Tampa, Florida, United States
🇺🇸Site Reference ID/Investigator# 66524, Orlando, Florida, United States
🇺🇸Site Reference ID/Investigator# 66526, Elk Grove Village, Illinois, United States
Surveillance of Synagis in Korean Pediatric Patients
- Conditions
- Respiratory Syncytial Virus Infection
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 618
- Registration Number
- NCT01537198
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 438
- Registration Number
- NCT01527916
- Locations
- 🇺🇸
Site Reference ID/Investigator# 82994, Jenkintown, Pennsylvania, United States
🇷🇺Site Reference ID/Investigator# 60946, Novosibirsk, Russian Federation
🇷🇺Site Reference ID/Investigator# 60958, St. Petersburg, Russian Federation
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 294
- Registration Number
- NCT01506609
- Locations
- 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 77373, Toronto, Ontario, Canada
🇺🇸The Angeles Clinic and Researc /ID# 60743, Los Angeles, California, United States
🇺🇸University of Pennsylvania /ID# 60753, Philadelphia, Pennsylvania, United States